SL
ABBV icon

Sentinus LLC’s AbbVie ABBV Stock Holding History

Sentinus LLC’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.45M Buy
38,836
+14,457
+59% +$3.21M 0.76% 38
2025
Q4 		$5.57M Buy
24,379
+3,446
+16% +$785K 0.54% 59
2025
Q3 		$4.85M Buy
20,933
+4,851
+30% +$988K 1.06% 28
2025
Q2 		$2.99M Buy
16,082
+101
+0.6% +$18.8K 0.73% 36
2025
Q1 		$3.35M Buy
15,981
+193
+1% +$37.5K 0.94% 30
2024
Q4 		$2.81M Buy
15,788
+239
+2% +$43.9K 0.82% 31
2024
Q3 		$3.07M Buy
15,549
+253
+2% +$47.2K 0.92% 26
2024
Q2 		$2.62M Buy
15,296
+1,223
+9% +$203K 0.85% 27
2024
Q1 		$2.56M Buy
+14,073
New +$2.43M 0.9% 26
2023
Q2 		$1.84M Sell
13,694
-138
-1% -$20.2K 0.58% 34
2023
Q1 		$2.2M Buy
13,832
+10,551
+322% +$1.61M 0.74% 28
2022
Q4 		$536K Sell
3,281
-9,565
-74% -$1.47M 0.31% 61
2022
Q3 		$1.72M Buy
+12,846
New +$1.84M 1.08% 23

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sentinus LLC's ABBV Position: Q1 2026 in Review

Sentinus LLC increased its AbbVie (ABBV) stake by 59% in Q1 2026, buying an estimated $3.21M and bringing the position to 38,836 shares worth $8.45M. The position accounts for 0.76% of the portfolio, ranked #38.

Sentinus LLC first reported a position in ABBV in Q3 2022 and has held it in 13 quarters since. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Sentinus LLC held 38,836 shares of AbbVie worth $8.45M as of Q1 2026.
  • Sentinus LLC bought 14,457 AbbVie shares in Q1 2026, an estimated $3.21M.
  • AbbVie made up 0.76% of Sentinus LLC's portfolio in Q1 2026, its #38 holding.
  • Sentinus LLC first reported a position in AbbVie in Q3 2022 and has held it in 13 quarters since.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Sentinus LLC's 13F filing for Q1 2026, filed 6 May 2026.